

(19) **DANMARK**

(10) **DK/EP 3110439 T3**



(12) **Oversættelse af  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 K 39/00 (2006.01)** **A 61 P 3/06 (2006.01)** **A 61 P 9/00 (2006.01)**  
**C 07 K 16/40 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2019-05-13**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-03-27**
- (86) Europæisk ansøgning nr.: **15714770.3**
- (86) Europæisk indleveringsdag: **2015-02-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-01-04**
- (86) International ansøgning nr.: **EP2015053725**
- (87) Internationalt publikationsnr.: **WO2015128287**
- (30) Prioritet: **2014-02-28 EP 14157221**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Affiris AG, Karl-Farkas-Gasse 22, Vienna 1030, Østrig**
- (72) Opfinder: **GALABOVA, Gergana, Affiris AG, Karl Farkasgasse 22, A-1030 Vienna, Østrig**  
**STAFFLER, Günther, Affiris AG, Karl Farkasgasse 22, A-1030 Vienna, Østrig**  
**BRUNNER, Sylvia, Affiris, Karl Farkasgasse 22, A-1030 Vienna, Østrig**  
**WINSAUER, Gabriele, Affiris AG, Karl Farkasgasse 22, A-1030 Vienna, Østrig**  
**MAIRHOFER, Andreas, Affiris AG, Karl Farkasgasse 22, A-1030 Vienna, Østrig**  
**JUNO, Claudia, Affiris AG, Karl Farkasgasse 22, A-1030 Vienna, Østrig**
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **PCSK9-VACCINER**
- (56) Fremdragne publikationer:  
**WO-A1-2011/117401**  
**WO-A1-2013/148284**  
**WO-A2-2011/027257**  
**WO-A2-2013/037889**  
**Y. LUO ET AL: "Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice", THE JOURNAL OF LIPID RESEARCH, vol. 50, no. 8, 1 August 2009 (2009-08-01) , pages 1581-1588, XP055126035, ISSN: 0022-2275, DOI: 10.1194/jlr.M800542-JLR200**



## DESCRIPTION

**[0001]** The present invention relates to immunogenic peptides capable to induce the formation of antibodies directed to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

**[0002]** Vascular disorders such as hypercholesterolemia, atherosclerosis, coronary heart disease and stroke are one of the main cause of death worldwide and elevated levels of Low Density Lipoprotein cholesterol (LDLc) are playing key role in their pathogenesis. Thus, LDLc management is a very important element for a successful treatment of dyslipidemia and atherosclerosis.

**[0003]** The discovery of PCSK9 in 2003 and its identification as the third factor, among LDLR and ApoB-100, involved in the development of the Autosomal Dominant Hypercholesterolemia (ADH), brought a new insight into the mechanism of the ADH disease development. Additionally, genetics studies in humans confirmed the connection between LDLc levels, PCSK9 and the onset of coronary heart disease. Link between PCSK9 and elevated LDLc has been also observed in different animal models.

**[0004]** PCSK9 is mainly expressed in the liver, intestine and kidney and is also found secreted in the blood stream. It directly interacts with the low density lipoprotein (LDL) receptor (LDLR), and the formed complex is subsequently internalized. By binding LDLR, PCSK9 promotes the receptor degradation and results in plasma LDLc elevation. "Gain of function mutations" (GOF) in the PCSK9 gene enhance its interaction with the LDLR, leading to markedly higher LDLc levels, subsequent hypercholesterolemia and predisposition to atherosclerosis. Whereas, PCSK9 "Loss of function mutations" (LOF) mutations are linked to reduced risk for coronary heart disease (CHD). Interestingly, two cases of healthy women having loss of functional PCSK9 and very low LDLc (~ 14mg/dL) highlighted PCSK9 as non-essential and as promising target for lowering LDLc levels in the blood stream.

**[0005]** PCSK9 over-expression in wild type mice reduces significantly the hepatic LDLR protein, despite the stable mRNA levels, leading to increased circulating LDLc. In comparison, overexpression of PCSK9 in LDLR  $-/-$  mice, does not influence the levels of LDLc, confirming the dependence of PCSK9 on LDLR for playing a role in the LDL catabolism. And as expected, PCSK9 $-/-$  mice showed a 2.8 fold increase in the levels of LDLR and reduction of LDLc compared to wild type animals. Finally, PCSK9 secretion in the circulation was abrogated, upon inactivation of PCSK9 in the liver tissue, confirming the liver as the major organ responsible for the PCSK9 secretion.

**[0006]** Thus, PCSK9 plays a crucial role in LDL catabolism through the direct actions on LDLR. Inhibition of PCSK9 turns to be beneficial for the LDLc levels. Therefore, anti-PCSK9 therapies are promising approach in terms of beneficial modulation of LDLc levels.

**[0007]** PCSK9, also known as neural apoptosis-regulated convertase 1 (NARC-1), is a

secreted proteinase K-like subtilase and member of the mammalian proprotein convertase (PC) family. It is synthesized as a ~72kDa proprotein and in order to be functional, the precursor (pro-PCSK9) is processed for autocatalysis. This results in the formation of a product (aa31-152) that binds non-covalently tight in 1:1 complex formation with the PCSK9 fragment (aa153-692) in this mature form (~60-63kDa) PCSK9 is proceeded towards the secretory pathway.

**[0008]** Additionally to this mature PCSK9 form, another truncated (furin cleaved) form of PCSK9 has been observed in many cell lines and blood plasma. Human and mouse plasma contains the two forms of PCSK9, mature (aa153-692) and its truncated version (aa218-692) and in mouse plasma the truncated form can represent up to ~ 50% of the total plasma PCSK9. This furin cleaved truncated PCSK9 is a product of the cleavage of mature PCSK9 (aa153-692) at the site aa218-219, therefore termed as furin/PC5/6A cleavage site. Upon such cleavage a subsequent PCSK9 truncated fragment (aa219-692) (so called furin cleaved PCSK9) is formed.

**[0009]** Recent data confirmed the ability of both forms: mature PCSK9 (aa153-692) and furin cleaved PCSK9 (aa219-aa692) to bind the low density lipoprotein receptor (LDLR) and thus regulate its level and therefore LDLc levels.

**[0010]** In the process of binding to LDLR, PCSK9 catalytic domain interacts with LDLR through different sites. As a result of this binding PCSK9 is positioning itself with the EGF (B) domain of the LDLR in a structural conformation which again strengthens and optimizes this interaction through a second site known as region where the furin/PC5/6A cleavage site (aa218-219) is positioned.

**[0011]** Thus, therapeutics targeting the furin/PC5/6A cleavage PCSK9 site (aa218-219) among their ability to abrogate the proper positioning of PCSK9 towards LDLR would be able to block the action of furin on PCSK9. Such therapeutics will in parallel abrogate the indirect PCSK9/LDLR interaction (positioning), and will inhibit the production of a truncated LDLR binding active form of PCSK9 (aa219-692). This would lead to beneficial increase of LDLR and therefore beneficial lowering of plasma LDLc.

**[0012]** Clinical trials throughout the last 25 years confirmed the clear benefit in treating cardiovascular diseases and lowering circulating LDLc levels by using 3-hydroxy-3 methyl-glutaryl coenzyme A reductase inhibitors (Statins). Statins are acting by inhibiting the hepatic cholesterol biosynthesis leading to subsequent increase in the Sterol-Regulatory Element Binding Protein (hereafter called SREBP). SREBP is a regulator of genes involved in the lipid homeostasis, such as LDLR. And the raised SREBP leads to increase LDLR protein levels and subsequent increase uptake of LDLc from the circulation.

**[0013]** Statins are the most common used therapy against dyslipidemia. But despite their efficacy, the treatment with statins is quite often linked to adverse effects such as raised liver enzymes, muscle pain and myositis. In addition, significant number of statin treated patients

fails to reach their goals in term of beneficial LDLc management and some of them are even statin intolerant. Interestingly, by acting on the SREBP statins not only increase the LDLR but also elevate the PCSK9 expression, leading to counteracting pharmacologic effect.

**[0014]** Thus, a combination of statins together with an anti-PCSK9 therapy was considered as promising approach for the LDLc management with potency of synergistic/additive effect in comparison to individual treatment.

**[0015]** And considerably the anti-PCSK9 therapies became even more attractive potential future LDLc modulator. That is suitable not only as a monotherapy, but also as a novel adjuvant therapy for most recommended and used current therapies such as statins or other substances such as fibrates or nicotinic acid. Meanwhile, several different strategies to suppress the synthesis or function of PCSK9 have been established. During the last decade approaches for inhibiting the synthesis by gene silencing with antisense-oligonucleotides (ASO), locked nucleic acid antisense-oligonucleotides (LNO-ASO) and siRNA have been quite actively developed. In addition, the ASO technology for inhibition of apolipoprotein-B has been successfully applied and recently approved by the Food and Drug Administration (FDA). In fact, application of siRNA against PCSK9 in monkeys (*Macaca fascicularis*) led to a significant reduction of total cholesterol. In general, the outcome from the different methods for PCSK9 gene silencing is controversial and apparently depends on the specificity of the approach. Two clinical phases I using siRNA and LNA-oligonucleotide faced some challenges, and were premature termination for uncertain reasons. However, on the other side a third clinical trial Phase I with inhibiting PCSK9 by siRNA was successfully terminated.

**[0016]** Other promising therapeutic approaches for inhibition of PCSK9-LDLR interaction by mimetic peptides and adnectins have been designed. But despite the different possibilities for inhibition, one of the most advanced approaches for reduction of LDLc by modulating PCSK9 are anti-PCSK9 monoclonal antibodies. To date, many clinical studies evaluating anti-PCSK9 monoclonal antibodies are currently ongoing. In Phase I clinical trials with healthy subjects, a single dose of anti-PCSK9 monoclonal antibody introduced intravenously or subcutaneously was able to reduce the LDLc levels up to 67%. Moreover, the same mAB applied subcutaneously bi-weekly or in 4 weeks interval in subjects on statin treatment succeeded a reduction of LDLc up to 81%. In addition, a phase II clinical trial with the same monoclonal antibody (bi-weekly treatment) in statin intolerant patients lowered the LDLc in the range of 41-66%. Those studies, confirmed that anti-PCSK9 therapy is efficient not only in healthy subjects, but also in statin treated and statin intolerant population. Furthermore, based on the positive outcome from the finalized clinical trials Phase III clinical trials to evaluate the effect of the mAB anti-PCSK9 therapy on patients with history of a prior myocardial infarction or stroke, coronary risk factors and coronary syndrome were performed and recently reported as meeting co-primary endpoints. However, one major issue of the PCSK9 monoclonal antibody therapies is the lack of a long-term persistent LDLc management.

**[0017]** WO 2009/055783 A2, WO 2009/100297 A1, WO 2010/057242 A2, WO 2011/02757 A2, WO 2011/117401 A1, WO 2012/59573 A1 WO 2013/037889 A2 and WO 2013/148284 A1

disclose vaccines with antigenic PCSK9 peptides. Luo et al. (J. Lipid Res. 50(2009): 1581-1588) discloses function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice.

**[0018]** An object of the present invention is to provide means and methods for reducing LDLc in an individual; it is a specific object of the present invention to provide new antigenic PCSK9 peptides as vaccines with improved antigenic potential and being efficient for reduction of cholesterol in vaccinated individuals. The present invention is defined by the appended claims.

**[0019]** The present invention concerns specific immunopotentiating variants (amino acid exchanges and optional truncations) of PCSK9 fragment consisting of amino acid residues 209 to 222 SEQ ID No.1.

**[0020]** The peptides of the present invention are so-called VARIOTOPE@s i.e. amino acid variations of the original, native sequence of the peptide PEEDGTRFHRQASK (SEQ.ID.No.1). VARIOTOPE@s have an amino acid sequence which is different from the original protein/peptide sequence from which they are derived. The VARIOTOPE@s according to the present invention are considered as foreign by the immune system and therefore do not need to break self-tolerance.

**[0021]** The present invention relates to a vaccine, vaccine composition or composition comprising at least one peptide consisting of a VARIOTOPE@ peptide or a peptide fragment thereof, derived from the PCSK9 fragment consisting of amino acid residues 209 to 222 (SEQ ID No.1), as defined in the claims.

**[0022]** The present disclosure also provides a vaccine comprising at least one peptide consisting of 9 to 25 amino acid residues, said peptide being a variant of the peptide PEEDGTRFHRQASK (SEQ.ID.No.1) with an increased immunogenicity in mammals, especially humans, compared to PEEDGTRFHRQASK (SEQ.ID.No.1) and wherein said variant is characterised by at least one and at most four amino acid exchanges compared to PEEDGTRFHRQASK (SEQ.ID.No.1).

**[0023]** The peptides provided with the present invention are immunopotentiating variants of the native PCSK9 amino acid sequence PEEDGTRFHRQASK (SEQ ID No.1). The peptides according to the present invention have been diligently designed and selected to provide an improved immune response against PCSK9 under careful consideration of self-tolerance issues usually connected to vaccines relying on native PCSK9 sequences.

**[0024]** The peptides according to the present invention have amino acid variations compared to the native sequence PEEDGTRFHRQASK (SEQ ID No.1). It is surprising that with such few amino acid exchanges, immunopotentiating peptide variations could be provided, especially with regard to their other beneficial property, namely that these novel peptides do not have to break self-tolerance.

**[0025]** Preferred peptides according to the present invention have an increased immunogenicity, compared to the peptide PEEDGTRFHRQASK (SEQ.ID.No.1), of at least 50 %, preferably at least 100 %, especially at least 200%, as evidenced in a serum ELISA, for example as evidenced by the example below.

**[0026]** According to a preferred embodiment, the peptides in the vaccine of the present invention have an increased ability to reduce total cholesterol levels, compared to the peptide PEEDGTRFHRQASK (SEQ.ID.No.1), of at least 3 %, preferably at least 5 %, especially at least 10%, as evidenced in a serum cholesterol test (in absolute figures, the untreated comparison being 100%), for example as evidenced by the example below. For the peptides according to the present invention, such enhanced total cholesterol lowering levels compared to the native sequence has been experimentally confirmed in a scientifically accepted cholesterol model. Accordingly, the variant according to the present invention is preferably selected from the group consisting of PEEDGTRFHRRASK (SEQ.ID.No.17), PEEDGTRFHRKASK (SEQ.ID.No.18), and PEEDGTRFHRTASK (SEQ.ID.No.36). Although it is already surprising that a variant peptide of the native sequence has an increased immunogenicity, compared to the native sequence peptide PEEDGTRFHRQASK (SEQ.ID.No.1), it was even more surprising that such peptides can also - in a scientifically accepted cholesterol model - reduce total cholesterol more efficient than the corresponding native sequence.

**[0027]** The peptides contained in the vaccines according to the present invention are preferably coupled or fused to a pharmaceutically acceptable carrier, preferably a carrier protein, especially a protein comprising at least one T cell epitope.

**[0028]** The administration of a vaccine according to the present invention allows treating or preventing pathological conditions linked to PCSK9 and its role in diseases such as dyslipidemia, hyperlipidemia, hypercholesterolemia and/or atherosclerosis.

**[0029]** The peptides of the present invention are variants (amino acid exchanges and optional truncations) of the PCSK9 fragment having amino acid sequence PEEDGTRFHRQASK (SEQ ID No.1). The PCSK9 VARIOTOPE® peptides according to the present invention are used in a form where the peptides consist of the sequences given (optionally with a linker attached to its N- or C-terminus, especially at its C-terminus; said linker being or containing preferably a cysteine residue, especially a cysteine residue at the C-terminus).

**[0030]** The vaccine of the present invention comprise at least one, at least 2, or at least 3, of the peptides defined herein and allows the active immunization of a mammal, in particular a human individual, where neutralizing antibodies to the PCSK9 are induced by vaccination with derived fragments, especially when coupled or fused to a peptide or polypeptide or a carrier protein (as a T cell epitope comprising molecule).

**[0031]** The peptide/carrier combination is mostly important since peptides of the present invention usually do not have the capacity to induce relevant amounts of antibodies when injected without coupling.

**[0032]** Thus the vaccine may comprise a combination of two or more peptides as disclosed herein. However, it is also possible that the vaccine of the present invention comprises next to one or more peptides linked to SEQ ID No. 1 and as defined herein also other peptides such as mimotopes (i.e. mutants of PCSK9 fragments ; EP12182241) or fragments of PCSK9 (see e.g. WO 2013/037889).

**[0033]** The peptides of the present invention can be chemically synthesized by methods which are well known in the art. Of course, it is also possible to produce the peptides of the present invention using recombinant methods. The peptides can also be produced in microorganisms such as bacteria, yeast or fungi, in eukaryotic cells such as mammalian or insect cells, or in a recombinant virus vector such as adenovirus, poxvirus, herpes virus, Simliki forest virus, baculovirus, bacteriophage, sindbis virus or Sendai virus. Suitable bacteria for producing the peptides include *E. coli*, *B. subtilis* or any other bacterium that is capable of expressing such peptides. Suitable yeast cells for expressing the peptides of the present invention include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Candida*, *Pichia pastoris* or any other yeast capable of expressing peptides. Corresponding means and methods are well known in the art. Also methods for isolating and purifying recombinantly produced peptides are well known in the art and include e.g. gel filtration, affinity chromatography, ion exchange chromatography etc.

**[0034]** The peptides according to the present invention are able to induce antibodies that specifically bind to human PCSK9 and inhibit the PCSK9-mediated degradation of LDLR.

**[0035]** To facilitate isolation of the peptides of the present invention, fusion polypeptides may be made wherein the peptides are translationally fused (covalently linked) to a heterologous polypeptide which enables isolation by affinity chromatography. Typical heterologous polypeptides are His-Tag (e.g. His<sub>6</sub>; 6 histidine residues), GST-Tag (Glutathione-S-transferase) etc. The fusion polypeptide facilitates not only the purification of the peptides but can also prevent the degradation of the peptides during the purification steps. If it is desired to remove the heterologous polypeptide after purification the fusion polypeptide may comprise a cleavage site at the junction between the peptide and the heterologous polypeptide. The cleavage site may consist of an amino acid sequence that is cleaved with an enzyme specific for the amino acid sequence at the site (e.g. proteases).

**[0036]** The vaccine and peptides of the present invention can be administered to any kind of mammal including humans. It is however preferred to administer the vaccine and peptides of the present invention to humans.

**Table A: Amino acid residues**

Amino acid	Three letter code	One letter code
alanine	ala	A
arginine	arg	R
asparagine	asn	N



Amino acid	Three letter code	One letter code
aspartic acid	asp	D
cysteine	cys	C
glutamic acid	glu	E
glutamine	gln	Q
glycine	gly	G
histidine	his	H
isoleucine	ile	I
leucine	leu	L
lysine	lys	K
methionine	met	M
phenylalanine	phe	F
proline	pro	P
serine	ser	S
threonine	thr	T
tryptophan	trp	W
tyrosine	tyr	Y
valine	val	V

**[0037]** According to a particularly preferred embodiment at least one peptide comprised in the vaccine of the present invention comprises at its N- and/or C-terminus at least one cysteine residue bound directly or via a spacer sequence thereto.

**[0038]** This cysteine residue may serve as a reactive group in order to bind the peptide to another molecule or a carrier. For instance, this group may be used to bind the peptide to a carrier protein. The cysteine residue can be bound directly to the peptides of the present invention or via a spacer sequence. The spacer sequence comprises preferably at least one, preferably at least two, more preferably at least three, even more preferably at least four, and optionally a maximum of ten, preferably a minimum of five small non-polar amino acid residues such as glycines.

**[0039]** It is, however, clear that such cysteine residue or other amino acid linkers (such as, e.g. CG-, CGG-, -GC, -GGC, etc.) are not to be regarded as (N- or C-terminal) exchanges or variations of the native PCSK9 peptide epitope PEEDGTRFHRQASK (SEQ.ID.No.1) or fragments thereof, but additions to the epitope sequence eliciting the specific antibody response in the vaccinated individual.

**[0040]** According to a preferred embodiment of the present invention the vaccine according to the present invention comprises a protein carrier, preferably a protein carrier selected from the

group consisting of keyhole limpet haemocyanin (KLH), CRM (preferably CRM197), tetanus toxoid (TT), diphtheria toxin (DT), protein D or any other protein or peptide containing helper T-cell epitopes.

**[0041]** According to the present invention the peptide is preferably coupled or fused to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin), CRM, tetanus toxoid, albumin-binding protein, bovine serum albumin, a dendrimer, peptide linkers (or flanking regions) as well as the adjuvant substances described in Singh et al. (Singh et al., Nat. Biotech. 17, (1999): 1075-1081 (in particular those in Table 1 of that document)), and O'Hagan et al. (O'Hagan and Valiante, Nature Reviews, Drug Discovery 2 (9); (2003): 727-735 (in particular the endogenous immuno-potentiating compounds and delivery systems described therein)), or mixtures thereof. The conjugation chemistry (e.g. via heterobifunctional compounds such as GMBS and of course also others as described in "Bioconjugate Techniques", Greg T. Hermanson) in this context can be selected from reactions known to the skilled man in the art.

**[0042]** Alternatively it is also possible to fuse the at least one peptide of the present invention to a protein carrier by methods known in the art. Such proteins comprise a peptide as described herein together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis, hepatitis proteins and protein D, a surface protein of the gram-negative bacterium Haemophilus influenza B (WO 91/18926). Preferably a protein D derivative is used which comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids) and which may be lipidated. Another carrier which may be used to provide fusion proteins may be the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from Streptococcus pneumoniae, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; Gene 43; (1986):265-292). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

**[0043]** According to a preferred embodiment of the present invention the peptide is formulated with an adjuvant, preferably adsorbed to aluminium hydroxide (Alhydrogel, Al(OH)<sub>3</sub>).

**[0044]** The vaccine according to the present invention may be formulated with an adjuvant, preferably a low soluble aluminum composition, in particular aluminum hydroxide. Of course, also adjuvants like MF59, aluminum phosphate, calcium phosphate, cytokines (e.g. IL-2, IL-12, GM-CSF), saponins (e.g. QS21), MDP derivatives, CpG oligonucleotides, LPS, MPL, polyphosphazenes, emulsions (e.g. Freund's, SAF), liposomes, virosomes, iscoms, cochleates, PLG microparticles, poloxamer particles, virus-like particles, heat-labile enterotoxin (LT), cholera toxin (CT), mutant toxins (e.g. LTK63 and LTR72), microparticles and/or polymerized liposomes may be used.

**[0045]** Suitable adjuvants are commercially available as, for example, AS01B, AS02A, AS15, AS-2 and derivatives thereof (GlaxoSmithKline, Philadelphia, PA); CWS, TDM, Leif, aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7 or -12 may also be used as adjuvants.

**[0046]** Preferred adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-O-deacylated monophosphoryl lipid A (3D-MPL), optionally with an aluminum salt (see, for example, Ribic et al., *Immunology and Immunopharmacology of Bacterial Endotoxins*, Plenum Publ. Corp., NY, (1986): 407-419; GB 2122204B; GB 2220211; and US 4,912,094). A preferred form of 3D-MPL is an emulsion having a small particle size less than 0.2 mm in diameter, and its method of manufacture is disclosed in WO 94/21292. Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO 98/43670. Exemplified preferred adjuvants include AS01B (MPL and QS21 in a liposome formulation), 3D-MPL and QS21 in a liposome formulation, AS02A (MPL and QS21 and an oil-in-water emulsion), 3D-MPL and QS21 and an oil-in-water emulsion, and AS 15. MPL adjuvants are disclosed e.g. in US 4,436,727; US 4,877,611; US 4,866,034 and US 4,912,094.

**[0047]** CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488, US 6,008,200 and US 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato et al., *Science* 273; (1996) :352. CpG when formulated into vaccines is generally administered in free solution together with free antigen (WO 96/02555; McCluskie and Davis, *supra*) or covalently conjugated to an antigen (WO 98/16247), or formulated with a carrier such as aluminium hydroxide ((Hepatitis surface antigen) Davis et al., *supra*; Brazolot-Millan et al., *PNAS USA*, 95(26), (1998):15553-8). CpG is known in the art as being an adjuvant that can be administered by both systemic and mucosal routes (WO 96/02555, EP 0 468 520, Davis et al., *J.Immunol*, 160(2), (1998):870-876; McCluskie and Davis, *J.Immunol.*, 161(9), (1998) :4463-6).

**[0048]** Another preferred adjuvant is a saponin or saponin mimetics or derivatives, preferably QS21 (Aquila Biopharmaceuticals Inc.), which may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210. Additional saponin adjuvants of use in the present invention include QS7 (described in WO 96/33739 and WO

96/11711) and QS17 (described in US 5,057,540 and EP 0 362 279 B1).

**[0049]** Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2, AS2', AS2, SBAS-4, or SBAS6, available from GlaxoSmithKline), Detox (Corixa), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs). Further example adjuvants include synthetic MPL and adjuvants based on Shiga toxin B subunit (see WO 2005/112991). It is particularly preferred to use aluminium hydroxide as adjuvant.

**[0050]** The vaccine of the present invention may be administered by any suitable route known for vaccines, preferably subcutaneously, intramuscularly, intradermally, or intravenously. Depending on the route of administration, the medicament may comprise respective carriers, adjuvants, and/or excipients.

**[0051]** A vaccine which comprises a peptide of the present invention and the pharmaceutically acceptable carrier may be administered by any suitable mode of application, e.g. intradermally (i.d.), intraperitoneally (i.p.), intramuscularly (i.m.), intranasally, orally, subcutaneously (s.c.), etc. and in any suitable delivery device (O'Hagan et al., Nature Reviews, Drug Discovery 2 (9), (2003), 727-735). The peptides of the present invention are preferably formulated for intradermal, subcutaneous or intramuscular administration. Means and methods for obtaining respective formulations are known to the person skilled in the art.

**[0052]** According to a preferred embodiment of the present invention the vaccine is used for the treatment and/or prevention of disorders caused by hyperlipidemia, hypercholesterolemia and/or atherosclerosis, preferably cardiovascular diseases, stroke or peripheral vascular diseases and other diseases linked to PCSK9, e.g. neoplastic diseases, such as melanoma and liver cancer metastasis (Sun et al, Neoplasia, 14(12) 2012, 1122-1131) in particular in mammals, preferably in humans.

**[0053]** As outlined, the peptides of the present invention are able to induce the formation of antibodies which are able to bind specifically PCSK9. The interaction of the antibodies with PCSK9 leads to the increase of low density lipoprotein receptor in liver hepatocytes *in vivo*, increased plasma cholesterol uptake and subsequent reduction of the plasma LDL cholesterol levels and thus the overall cholesterol levels.

**[0054]** In particular, the present invention discloses antibodies able to bind the aa209-222 PCSK9 region and negatively influence the PCSK9/LDLR interaction and therefore beneficially reduce plasma cholesterol. Those antibodies also block the cleavage of the mature PCSK9 (aa153-692) protein by furin and therefore inhibit the production of LDLR binding truncated form of PCSK9 (aa219-692). Additionally, the peptides of the present invention are able to induce the formation of antibodies which are able to bind PCSK9 in the region 209-222 and inhibit the process of furin cleavage of the mature PCSK9.

**[0055]** The disease associated with atherosclerosis is preferably selected from the group

consisting of peripheral arterial occlusive disease, coronary heart disease, apoplectic cerebral insultus and stroke.

**[0056]** The terms "diseases associated with hyperlipidemia, hypercholesterolemia and/or atherosclerosis" and "disorders caused by hyperlipidemia, hypercholesterolemia and/or atherosclerosis" refer to diseases which are a consequence of hyperlipidemia, hypercholesterolemia and atherosclerosis. These diseases include among others peripheral arterial occlusive disease, coronary heart disease and apoplectic cerebral insultus (see e.g. Steinberg, D. J Lipid Res 46(2005):179-190 and Steinberg, D. J Lipid Res 47(2006):1339-1351).

**[0057]** According to a preferred embodiment of the present invention the peptides of the present invention are administered to a mammal or an individual in an amount of 0.1 ng to 10 mg, preferably of 0.5 to 500 µg, more preferably 1 to 100 µg, per immunization. In a preferred embodiment these amounts refer to all peptides (if more than one peptide is used in the vaccine) present in the vaccine. In another preferred embodiment these amounts refer to each single fragment present in the vaccine. It is of course possible to provide a vaccine in which the peptides are present in different or equal amounts. However, the peptides of the present invention may alternatively be administered to a mammal or an individual in an amount of 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 300 µg/kg body weight.

**[0058]** The amount of peptides that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. The dose of the vaccine may vary according to factors such as the disease state, age, sex and weight of the mammal or individual, and the ability of antibody to elicit a desired response in the individual. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The dose of the vaccine may also be varied to provide optimum preventative dose response depending upon the circumstances. For instance, the peptides and vaccine of the present invention may be administered to an individual at intervals of several days, one or two weeks or even months or years depending always on the level of antibodies directed to PCSK9.

**[0059]** In a preferred embodiment of the present invention the peptide/vaccine is applied between 2 and 10, preferably between 2 and 7, and most preferably up to 5. This number of immunizations may lead to a basic immunisation. In a particularly preferred embodiment the time interval between the subsequent vaccinations is chosen to be between 2 weeks and 5 years, preferably between 1 month and up to 3 years, more preferably between 2 months and 1.5 years. An exemplified vaccination schedule may comprise 3 to 4 initial vaccinations over a period of 6 to 8 weeks and up to 6 months, preferably followed with further administrations after such initial vaccinations. Thereafter the vaccination may e.g. be repeated every two to ten years. The repeated administration of the peptide/vaccine of the present invention may maximize the final effect of a therapeutic vaccination.

**[0060]** The vaccine of the present invention may also comprise antigens derived from other proteins. For examples proteins involved in the regulation of the LDL and/or HDL levels within a human body. For instance, the PCSK9 fragments of the present invention may be combined with epitopes derived from human CETP protein. The vaccine of the present invention may also comprise antigens derived from a different epitope of the PCSK9 protein.

**[0061]** The vaccine of the present invention may also comprise antigens derived from other proteins suitable for the treatment of hyperlipidemia, hypercholesterolemia and/or atherosclerosis, preferably cardiovascular diseases, stroke or peripheral vascular diseases.

**[0062]** Typically, the vaccine contains the peptides of the present invention in an amount of 0.5 to 500 µg, preferably 1 to 100 µg and alternatively from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 µg, or, alternatively, e.g. 100 fmol to 10 µmol, preferably 10 pmol to 1 µmol, in particular 100 pmol to 100 nmol. Typically, the vaccine may also contain auxiliary substances, e.g. buffers, stabilizers etc.

**[0063]** Yet another aspect of the present invention relates to a method for treating an individual suffering or at risk to suffer from atherosclerosis or a disease associated with atherosclerosis in the course of which a peptide or vaccine according to the present invention is administered to said individual.

**[0064]** Next to the vaccine of the present invention, the individual to be treated may receive also other active ingredients known to influence the LDL and/or HDL levels in humans and mammals such as statins, fibrates, nicotinic acid, cholesterol uptake inhibitor (e.g. ezetimibe), ApoA1 Milano, delipidated HDL, plant sterols. It is particularly preferred to administer to an individual the vaccine of the present invention together (i.e. at the same time, consecutively etc.) with statins. The vaccine of the present invention can also be combined with methods like LDL apheresis. LDL apheresis is a form of apheresis to eliminate the cholesterol-containing particle low-density lipoprotein (LDL) from the bloodstream. Typically LDL apheresis works by leading venous blood through a column coated with antibodies to apolipoprotein B (the main protein of LDL particles), dextran sulfate or polyacrylate, or by precipitating LDL with heparin at low pH. Respective methods are known to a person skilled in the art.

**[0065]** The term "preventing", as used herein, covers measures not only to prevent the occurrence of disease, such as risk factor reduction, but also to arrest its progress and reduce its consequences once established.

**[0066]** As used herein, the term "treatment" or grammatical equivalents encompasses the improvement and/or reversal of the symptoms of disease. A compound which causes an improvement in any parameter associated with disease when used in the screening methods of the instant invention may thereby be identified as a therapeutic compound. The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. For example, those who may benefit from treatment with compositions and methods of the present invention include those already with a disease and/or disorder as well as those in

which a disease and/or disorder is to be prevented (e.g., using a prophylactic treatment of the present invention).

**[0067]** The present invention is further illustrated by the following example and the figures, however, without being restricted thereto.

**Fig. 1 Protein ELISA**

**[0068]**

Figure 1A and 1B show comparison of the mean titers (n=5 mice/group) against human PCSK9 protein induced by the indicated sequences.

The data reveal the ability of the selected VARIOTOPEs® to induce higher antibodies titers against human PCSK9 protein in comparison to the native sequence (Seq 1: PEEDGTRFHRQASK). Fig. 2 % Total Cholesterol in comparison to the negative control group set as 100%.

Figure 2A shows comparison of the % mean (n=3 mice/group) total cholesterol levels of mice immunized with selected immunogenic VARIOTOPE®s (Seq 10: PQEDGTRFHRQASK, Seq 17: PEEDGTRFHRRASK, Seq 18: PEEDGTRFHRKASK, Seq 23: PEEDGTRFHRQASR) in comparison to a negative control group immunized with irrelevant peptide and to the native original PCSK9 sequence (Seq 1: PEEDGTRFHRQASK). Note the ability of the VARIOTOPE®s to reduce the total cholesterol levels to similar or even lower levels in comparison to the native sequence.

Figure 2B shows comparison of the % mean (n=5 mice/group) total cholesterol levels of mice immunized with selected immunogenic VARIOTOPE® (Seq 36: PEEDGTRFHRTASK) in comparison to a negative control group immunized with irrelevant peptide and to the native original PCSK9 sequence (Seq 1: PEEDGTRFHRQASK). Note the ability of the VARIOTOPE® to reduce the total cholesterol levels stronger in comparison to the native sequence.

Figure 2C shows comparison of the % (n=5 mice/group) total cholesterol levels of mice immunized with selected VARIOTOPE® with multiple aa exchanges (Seq 41: PEEDGSRFHKQASK and Seq 44: PEEDGSRFHRQATK) in comparison to a negative control group immunized with irrelevant peptide and to the native original PCSK9 sequence (Seq 1: PEEDGTRFHRQASK). Note the ability of the VARIOTOPE®s to reduce the total cholesterol levels stronger in comparison to the native sequence.

Fig. 3. Inhibition of furin cleavage and production of truncated furin cleaved PCSK9.

Figure 3 reveals the ability of selected high immunogenic VARIOTOPE®s (Seq 10: PQEDGTRFHRQASK, Seq 17: PEEDGTRFHRRASK, Seq 18: PEEDGTRFHRKASK, Seq 23: PEEDGTRFHRQASR) to induce antibodies that are able to inhibit the furin cleavage of the mature PCSK9 (aa153-692) and thus abrogate the production of truncated PCSK9 (~50kDa product) (aa219-692). The cleavage process is compared to negative control (PCSK9

incubated with plasma from mice injected with irrelevant peptide) and positive controls (huPCSK9 incubated with or without furin).

Figure 4 shows % total cholesterol (TC) in comparison to the negative control group set as 100%.

Figure 5 shows % difference of TC of VARITOPE® treated groups in comparison to the group treated with the original sequence set to 0.

Figure 6 shows % difference of TC of VARITOPE® treated groups in comparison to the group treated with the original sequence set to 0.

**EXAMPLES:**

**Materials and Methods**

***Vaccine:***

**[0069]** The peptides were conjugated via the heterobifunctional linker GMBS (4-Maleimidobutyric acid N-hydroxysuccinimide ester) to KLH (Keyhole Limpet Hemocyanin).

***Animal experiments:***

**[0070]** 5 BALB/c mice were subcutaneously immunized. Mice had access to food and water ad libitum and were kept under a 12 h light/dark cycle. The age of mice at the beginning of experiments was 8 to 10 weeks.

**[0071]** Mice were injected four times in 2 week intervals with 15 µg of net peptide coupled to KLH and adsorbed to Alhydrogel as adjuvant in a volume of 1 ml in total.

**[0072]** Blood was taken approximately 2 weeks after the final injection.

***Protein ELISA:***

**[0073]** To determine the immunogenicity of the vaccines, and thus to identify the amount of PCSK9 specific antibodies in the plasma of immunized animals, ELISA immunoassay was performed. The ELISA immunoassay generates a signal which can be easily quantified and



represents a quantitative measure of the amount of vaccine induced PCSK9-specific antibodies. Thus the titers as measured by ELISA correlate directly with the amount ( $\mu\text{g/ml}$ ) of target specific antibodies in the plasma sample of treated animals. All plasma samples were collected two weeks after the final immunization and equally treated. In order to have a direct comparison, the quantitative evaluation by the PCSK9 Protein ELISA immunoassay of the vaccine induced PCSK9-specific antibodies and the comparison to their relative controls (originals sequence and negative control) was performed for all samples simultaneously. For this purpose, ELISA plates were coated with recombinantly expressed human PCSK9 protein. Unspecific binding was blocked by incubation with blocking buffer (1% BSA in PBS). Appropriate serum dilutions (with a starting dilution of 1:100) were added to the wells, serially diluted 1:2 fold (12 dilution steps) and incubated for approximately 1 hour. Bound antibodies were detected by incubation with anti-mouse IgG antibody, ABTS was added as substrate and the OD at 405 nm was measured. As negative control sera from the control group injected with an irrelevant peptide were analyzed. The titers were defined as the dilution of the serum where 50% of the OD<sub>max</sub> in the assay is reached.

#### ***Total Cholesterol assay:***

**[0074]** All plasma samples were collected two weeks after the final immunization and equally treated. Total cholesterol (TC) measurements were performed simultaneously for all samples and side by side compared to their related controls (originals sequence and negative control). The simultaneous quantitative measurement of the plasma TC levels in mg/dL was measured by LabAssay™ Cholesterol Kit (Wako). In details, upon incubation with the chromogen reagent containing cholesterol esterase, the cholesterol esters in the samples were decomposed into free cholesterol and fatty acids. Subsequently the free cholesterol was oxidized by the cholesterol oxidase, leading to the simultaneously release of hydrogen peroxide. The produced hydrogen peroxide let DAOS and 4-Aminoantipyrin oxidize and condensate quantitatively by peroxidase (HRP), which produced blue pigment. Optical density was measured at 600nm and quantification of the TC was calculated according to a standard curve.

#### ***Inhibition of Furin cleavage***

**[0075]** The furin cleavage reaction was performed with 2 Units Furin (~110ng) (New England Biolabs) in PCSK9 buffer containing 100 mM Hepes Buffer pH 7.5, 5% Triton-X and 1mM CaCl. In details, 4 $\mu\text{l}$  mouse plasma from VARIOTOPE@s vaccinated mice was incubated with 250ng biotinylated huPCSK9 (BPS Bioscience) in PCSK9 buffer for 1h at room temperature. Subsequently, 2U Furin (~110ng) (New England Biolabs) was added to the reaction solution and incubated over night at RT. The reaction product was analyzed by SDS-PAGE under reducing conditions.

#### **Results:**

[0076]

1. Sequence information and titers against huPCSK9 (OD<sub>max/2</sub>):

Seq ID	Sequence	OD <sub>max/2</sub>
Seq 1	PEEDGTRFHRQASK	12074
Seq 2	AEEDGTRFHRQASK	36869
Seq 3	PAEDGTRFHRQASK	2774
Seq 4	PEEDGTRFARQASK	21494
Seq 5	PEEDGTRFHAQASK	33442
Seq 6	PEEDGTRFHRAASK	22475
Seq 7	PEEDGTRFHRQAAK	15676
Seq 8	PEEDGTRFHRQASA	23638
Seq 9	TEEDGTRFHRQASK	23944
Seq 10	PQEDGTRFHRQASK	29228
Seq 11	PKEDGTRFHRQASK	6610
Seq 12	PEEDGSRFHRQASK	12636
Seq 13	PEEDGTRFHQQASK	18490
Seq 14	PEEDGTRFHKQASK	17795
Seq 15	PEEDGTRFHMQASK	15556
Seq 16	PEEDGTRFHREASK	18670
Seq 17	PEEDGTRFHRRASK	28996
Seq 18	PEEDGTRFHRKASK	30537
Seq 19	PEEDGTRFHRQSSK	41310
Seq 20	PEEDGTRFHRQATK	10813
Seq 21	PEEDGTRFHRQANK	15303
Seq 22	PEEDGTRFHRQALK	8694
Seq 23	PEEDGTRFHRQASR	14722
Seq 24	PEEDGTRFHRQASL	19471
Seq 25	KEEDGTRFHRQASK	19315
Seq 26	PEWDGTRFHRQASK	840
Seq 27	PEEDKTRFHRQASK	7154
Seq 28	PEEDGTGFHRQASK	0
Seq 29	PEEDGTRFSRQASK	33111
Seq 30	PEEDGTRFTRQASK	9519
Seq 31	PEEDGTRFVRQASK	11850

Seq ID	Sequence	ODmax/2
Seq 32	PEEDGTRFGRQASK	822
Seq 33	PEEDGTRFMRQASK	10651
Seq 34	PEEDGTRFHPQASK	20318
Seq 35	PEEDGTRFHSQASK	29223
Seq 36	PEEDGTRFHRTASK	29984
Seq 37	PEEDGTRFHRQTSK	25826
Seq 38	PEEDGTRFHRQASS	31481
Seq 39	PEEDGTRFHRQAST	13172
Seq 40	PEEDGTRFHRQASV	22678
Seq 41	PEEDGSRFHKQASK	37296
Seq 42	PEEDGSRFHMQASK	18599
Seq 43	PEEDGSRFHRRASK	29435
Seq 44	PEEDGSRFHRQATK	20684
Seq 45	PEEDGSRFHRRATK	11097
Seq 46	X <sub>1</sub> X <sub>2</sub> EDGX <sub>6</sub> RFX <sub>9</sub> X <sub>10</sub> X <sub>11</sub> X <sub>12</sub> X <sub>13</sub> X <sub>14</sub>	

These results are also depicted in Fig. 1. According to the present invention, those VARIOPTOPEs® that have the potential to elicit a higher titer against huPCSK9 (e.g. measured as ODmax/2) according to the present example) are regarded as immunopotentiating variants of the native sequence PEEDGTRFHRQASK. A preferred VARIOPTOPE® according to the present invention has a pronounced immunopotentiating property (measured e.g. as an ODmax/2 in the present example of above 20000 or as a raising this effect to 150%, preferably of doubling of this effect, compared to the native sequence). An even more preferred VARIOPTOPE® according to the present invention has an even more pronounced immunopotentiating property (measured e.g. as an ODmax/2 in the present example of above 25000, preferably of above 30000; or as a tripling of this effect, compared to the native sequence).

2. Total Cholesterol in % compared to the control group set as 100% in mice immunized with VARIOPTOPE®s with single AA exchange (Seq 10, 17, 18 and 23; Figure 2A and and Seq 36 2B) and multiple exchanges (Seq 41, 44; Figure 2C).

Figure 2A

TC in %		
	Negative Control	100
Seq 1	PEEDGTRFHRQASK (original sequence)	81
Seq 10	PQEDGTRFHRQASK	78
Seq 17	PEEDGTRFHRRASK	81
Seq 18	PEEDGTRFHRKASK	81

TC in %		
	Negative Control	100
Seq 23	PEEDGTRFHRQASR	70

Figure 2B

TC in %		
	Negative Control	100
Seq 1	PEEDGTRFH RQASK (original sequence)	89
Seq 36	PEEDGTRFHRTASK	72

Figure 2C

TC in % multiple AA exchanges		
	Negative Control	100
Seq 1	PEEDGTRFHRQASK (original sequence)	81
Seq 41	PEEDGSRFHKQASK	66
Seq 44	PEEDGSRFHRQATK	74

These results are also depicted in Fig. 2. According to the present invention, those VARIOPTOPEs® that have the potential to elicit a comparable reduction of TC compared to the native sequence PEEDGTRFHRQASK are preferred. Of course, an even more preferred VARIOPTOPE® according to the present invention has the ability to reduce TC to an even higher amount than the native sequence (measured e.g. as a reduction in % TC as measured in the present example of more than 5 %, especially more than 10% (absolute, i.e. compared to the negative control), compared to the native sequence).

3. Western blot analysis reveals the ability of the induced antibodies upon immunization with Seq 10, 17, 18 and 23 to inhibit the formation of truncated furin cleaved PCSK9 (a219-692; ~50kDa) (see Fig. 3).

### Reduction of total cholesterol (TC) in treated animals

[0077] Additional experiments were performed in order to deliver further experimental evidence showing that the capacity of selected VARIOPTOPE® vaccine candidates have the ability to reduce total cholesterol (TC) in treated animals to a higher extent than a vaccine containing the corresponding native (original) sequence.

[0078] Peptides used for immunizations in the following experiments:

Seq 1:	PEEDGTRFHRQASK (original native Sequence)
Seq 2 :	A <del>E</del> EDGTRFHRQASK
Seq 9:	I <del>E</del> EDGTRFHRQASK
Seq 10:	P <del>Q</del> EDGTRFHRQASK
Seq 17:	PEEDGTRFHR <del>R</del> ASK

Seq 18:	PEEDGTRFHRKASK
Seq 23:	PEEDGTRFHRQASR
Seq 36:	PEEDGTRFHRTASK
Seq 24:	PEEDGTRFHRQASL

**[0079]** In order to evaluate the ability of selected VARIOTOPE® vaccine candidates to reduce TC and to compare the magnitude of TC reduction in VARIOTOPE® treated animals with the TC reduction in animals treated with a vaccine containing the original sequence, 5 to 10 mice per group were injected five times in 2 week intervals with vaccines containing 1 µg of net peptide. As usual, antigenic peptides were coupled to KLH and adsorbed to 0.2% Alhydrogel as adjuvant in a volume of 1 ml in total. For the described experiments GMP-like material was used. Blood samples were taken approximately 2 weeks after the final injection.

**[0080]** In a first experiment, vaccines containing the original sequence and containing the following VARIOTOPE®s were tested:

Seq 1:	PEEDGTRFHRQASK
Seq 9:	TEEDGTRFHRQASK
Seq 17:	PEEDGTRFHRRASK
Seq 18:	PEEDGTRFHRKASK
Seq 23:	PEEDGTRFHRQASR

**[0081]** In order to include a vaccine known to be able to reduce TC levels in treated animals but to be inferior in reducing TC levels compared to the vaccine containing the original sequence the following peptide vaccine was included in this experiment: Seq 24: PEEDGTRFHRQASL

**[0082]** As already outlined above (Figure 1A), all vaccine candidates are highly immunogenic and have the capacity to induce an antibody response that effectively bind to huPCSK9 as well as mouse PCSK9. In order to prove efficacy of the induced antibodies, TC measurements of blood samples derived from individual mice were performed. Figure 4 depicts relative group mean TC values (in %) compared to the control group set as 100%. In this experiment 5 animals per group were immunized. As can be seen, in all vaccine treated groups TC values were significantly reduced in comparison to the control group.

**[0083]** Since the aim of this experiment was to compare VARIOTOPE® treated groups with the group treated with the original native sequence, in Figure 5 the % reduction of TC values of vaccine treated groups compared to the group treated with the original sequence set to 0% is presented.

**[0084]** As depicted in Figure 5 vaccines containing the sequences

Seq 9:	TEEDGTRFHRQASK
Seq 17:	PEEDGTRFHRRASK
Seq 18:	PEEDGTRFHRKASK
Seq 23:	PEEDGTRFHRQASR

are 3 to 10% more powerful to reduce TC levels in comparison to the vaccine containing the original sequence. In contrast to this, the vaccine containing the Seq 24: PEEDGTRFHRQASK possesses the ability to reduce TC levels compared to the negative control (Figure 4) but compared to the original peptide containing vaccine the TC levels were higher (+9%).

**[0085]** In a further experiment following VARIOTOPE®s were tested and compared again to Seq 1:

Seq 2:	AEEDGTRFHRQASK
Seq 10:	PQEDGTRFHRQASK
Seq 36:	PEEDGTRFHRTASK

**[0086]** In this experiment 10 animals per group were injected five times in 2 week intervals with vaccines containing 1 µg of net peptide. Blood samples were taken again approximately 2 weeks after the final injection. In order to compare TC reduction in these animals directly with the TC values in animals treated with the original sequence % reduction of TC values of VARIOTOPE® vaccine treated groups compared to the group treated with the original sequence set to 0% is presented in Figure 6.

**[0087]** As shown in Figure 6 all three vaccine candidates tested in this experiment were more powerful in reducing TC levels compared to the vaccine containing the original sequence (-7% to -13%).

**[0088]** Based on the disclosure, the following preferred aspects can be specifically highlighted:

1. Vaccine comprising at least one peptide consisting of 9 to 25 amino acid residues, said peptide being a variant of the peptide PEEDGTRFHRQASK (SEQ.ID.No.1) with an increased immunogenicity in mammals, especially humans, compared to PEEDGTRFHRQASK (SEQ.ID.No.1) and wherein said variant is characterised by at least one and at most four amino acid exchanges compared to PEEDGTRFHRQASK (SEQ.ID.No.1), wherein said variant is preferably selected from the group consisting of AEEDGTRFHRQASK (SEQ.ID.No.2), TEEDGTRFHRQASK (SEQ.ID.No.9), PQEDGTRFHRQASK (SEQ.ID.No.10), PEEDGTRFHRRASK (SEQ.ID.No.17), PEEDGTRFHRKASK (SEQ.ID.No.18), PEEDGTRFHRQASR (SEQ.ID.No.23), and PEEDGTRFHRTASK (SEQ.ID.No.36).
2. Vaccine according to embodiment 1, comprising at least one peptide consisting of 9 to 25 amino acid residues, said peptide having or comprising the amino acid sequence

$X_1X_2EDGX_6RFX_9X_{10}X_{11}X_{12}X_{13}X_{14}$ , (SEQ ID No. 46),

wherein

$X_1$  is an amino acid residue selected from the group consisting of lysine, threonine, alanine and proline, preferably alanine or proline,

$X_2$  is glutamine or aspartic acid, preferably aspartic acid,

$X_6$  is threonine or serine,

$X_9$  is an amino acid residue selected from the group consisting of histidine, alanine and serine,

$X_{10}$  is an amino acid residue selected from the group consisting of arginine, alanine, glutamine, lysine, methionine, proline and serine, preferably arginine, serine or alanine,

$X_{11}$  is an amino acid residue selected from the group consisting of glutamine, alanine, glutamic acid, lysine, threonine, and arginine, preferably glutamine, lysine, arginine, and threonine,

$X_{12}$  is an amino acid residue selected from the group consisting of alanine, serine and threonine, preferably alanine or serine,

$X_{13}$  is an amino acid residue selected from the group consisting of serine, alanine, and asparagine, preferably serine,

$X_{14}$  is an amino acid residue selected from the group consisting of lysine, alanine, arginine, leucine, serine, threonine, and valine, preferably lysine or serine,

or a fragment of SEQ.ID.No.46 having at least 9 consecutive amino acid residues, and wherein SEQ ID No. 46 is not PEEDGTRFHRQASK (SEQ.ID.No.1) or a N- or C-terminally truncated fragment thereof.

3. 3. Vaccine according to embodiment 1 or 2, wherein the peptide consists or comprises an amino acid sequence selected from the group consisting of AEEDGTRFHRQASK, PEEDGTRFARQASK, PEEDGTRFHAQASK, PEEDGTRFHRAASK, PEEDGTRFHRQAAK, PEEDGTRFHRQASA, TEEDGTRFHRQASK, PQEDGTRFHRQASK, PEEDGSRFHRQASK, PEEDGTRFHQQASK, PEEDGTRFHKQASK, PEEDGTRFHMQASK, PEEDGTRFHREASK, PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRQSSK, PEEDGTRFHRQANK, PEEDGTRFHRQASR, PEEDGTRFHRQASL, KEEDGTRFHRQASK, PEEDGTRFSRQASK, PEEDGTRFMRQASK, PEEDGTRFHPQASK, PEEDGTRFHSQASK, PEEDGTRFHRTASK, PEEDGTRFHRQTSK, PEEDGTRFHRQASS, PEEDGTRFHRQAST, PEEDGTRFHRQASV, PEEDGSRFHKQASK, PEEDGSRFHMQASK, PEEDGSRFHRRASK, and PEEDGSRFHRQATK; preferably AEEDGTRFHRQASK, PEEDGTRFARQASK, PEEDGTRFHAQASK, PEEDGTRFHRAASK, PEEDGTRFHRQASA, TEEDGTRFHRQASK, PQEDGTRFHRQASK, PEEDGTRFHRRASK,

PEEDGTRFHRKASK, PEEDGTRFHRQSSK, PEEDGTRFSRQASK, PEEDGTRFHPQASK, PEEDGTRFHSQASK, PEEDGTRFHRTASK, PEEDGTRFHRQTSK, PEEDGTRFHRQASS, PEEDGTRFHRQASV, PEEDGSRFHKQASK, PEEDGSRFHRRASK, and PEEDGSRFHRQATK; especially AEEDGTRFHRQASK, PEEDGTRFHAQASK, PQEDGTRFHRQASK, PEEDGTRFHRRASK PEEDGTRFHRKASK, PEEDGTRFHRQSSK, PEEDGTRFSRQASK, PEEDGTRFHSQASK, PEEDGTRFHRTASK, PEEDGTRFHRQTSK, PEEDGTRFHRQASS, PEEDGSRFHKQASK and PEEDGSRFHRRASK.

4. 4. Vaccine according to any one of embodiments 1 to 3, wherein said at least one peptide is coupled or fused to a pharmaceutically acceptable carrier.
5. 5. Vaccine according to any one of embodiments 1 to 4, wherein the at least one peptide comprises at its N- and/or C-terminus at least one cysteine residue bound directly or via a spacer sequence thereto.
6. 6. Vaccine according to embodiment 4 or 5, wherein the pharmaceutically acceptable carrier is a protein carrier.
7. 7. Vaccine according to embodiment 6, wherein the protein carrier is selected from the group consisting of keyhole limpet haemocyanin (KLH), tetanus toxoid (TT), CRM197, protein D or a diphtheria toxin (DT), preferably a mutated diphtheria toxin, CRM197, or KLH, especially KLH.
8. 8. Vaccine according to any one of embodiments 1 to 7, wherein the vaccine is formulated with an adjuvant, preferably with Al(OH)<sub>3</sub> (Alhydrogel).
9. 9. Vaccine according to any one of embodiments 1 to 8, wherein said at least one peptide consists of 9 to 20 amino acid residues, especially 9 to 15 amino acid residues.
10. 10. Vaccine according to any one of embodiments 1 to 9, wherein said at least one peptide consists of 10, 11, 12, 13, 14 or 15 amino acid residues, preferably 13 or 14 amino acid residues, especially 14 amino acid residues.
11. 11. Vaccine according to any one of embodiments 1 to 10, comprising at least 2, at least 3, or at least 4 of said peptides consisting of 9 to 25 amino acid residues.
12. 12. Vaccine according to any one of embodiments 1 to 11, comprising the at least one peptide in an amount of 0.1 ng to 10 mg, preferably of 0.5 to 500 µg, more preferably 1 to 100 µg.
13. 13. Vaccine according to any one of embodiments 1 to 12, wherein the peptide has an increased immunogenicity, compared to the peptide PEEDGTRFHRQASK (SEQ.ID.No.1), of at least 50 %, preferably at least 100 %, especially at least 200%, as evidenced in a serum ELISA.
14. 14. Vaccine according to any one of embodiments 1 to 13, wherein the peptide has an increased ability to reduce total cholesterol levels, compared to the peptide PEEDGTRFHRQASK (SEQ.ID.No.1), of at least 3 %, preferably at least 5 %, especially at least 10%, as evidenced in a serum cholesterol test.
15. 15. Vaccine according to any one of embodiments 1 to 14 for use in a method for treating and/or preventing disorders caused by hyperlipidemia, hypercholesterolemia and/or atherosclerosis, preferably cardiovascular diseases, stroke or peripheral vascular diseases, or neoplastic diseases, preferably melanoma and liver cancer metastasis linked to PCSK9.
16. 16. Peptide consisting of 9 to 25 amino acid residues, said peptide being a variant of the



peptide PEEDGTRFHRQASK (SEQ.ID.No.1) with an increased immunogenicity in mammals, especially humans, compared to PEEDGTRFHRQASK (SEQ.ID.No.1) and wherein said variant is characterised by at least one and at most four amino acid exchanges compared to PEEDGTRFHRQASK (SEQ.ID.No.1) .

17. 17. Peptide according to embodiment 16, consisting of 9 to 25 amino acid residues, said peptide having or comprising the amino acid sequence

X<sub>1</sub>X<sub>2</sub>XEDGX<sub>6</sub>RFX<sub>9</sub>X<sub>10</sub>X<sub>11</sub>X<sub>12</sub>X<sub>13</sub>X<sub>14</sub>, (SEQ ID No. 46),

wherein

X<sub>1</sub> is an amino acid residue selected from the group consisting of lysine, threonine, alanine and proline, preferably alanine or proline,

X<sub>2</sub> is glutamine or aspartic acid, preferably aspartic acid,

X<sub>6</sub> is threonine or serine,

X<sub>9</sub> is an amino acid residue selected from the group consisting of histidine, alanine and serine

X<sub>10</sub> is an amino acid residue selected from the group consisting of arginine, alanine, glutamine, lysine, methionine, proline and serine, preferably arginine, serine or alanine,

X<sub>11</sub> is an amino acid residue selected from the group consisting of glutamine, alanine, glutamic acid, lysine, threonine, and arginine, preferably glutamine, lysine, arginine, and threonine,

X<sub>12</sub> is an amino acid residue selected from the group consisting of alanine, serine and threonine, preferably alanine or serine,

X<sub>13</sub> is an amino acid residue selected from the group consisting of serine, alanine, and asparagine, preferably serine,

X<sub>14</sub> is an amino acid residue selected from the group consisting of lysine, alanine, arginine, leucine, serine, threonine, and valine, preferably lysine or serine,

or a fragment of SEQ.ID.No.46 having at least 9 consecutive amino acid residues, and wherein SEQ ID No. 46 is not PEEDGTRFHRQASK (SEQ.ID.No.1) or a N- or C-terminally truncated fragment thereof.

18. 18. Peptide according to embodiment 16 or 17, wherein the peptide consists or comprises an amino acid sequence selected from the group consisting of  
 AEEDGTRFHRQASK, PEEDGTRFARQASK, PEEDGTRFHAQASK, PEEDGTRFHRAASK,  
 PEEDGTRFHRQAAK, PEEDGTRFHRQASA, TEEDGTRFHRQASK,  
 PQEDGTRFHRQASK, PEEDGSRFHRQASK, PEEDGTRFHQQASK,  
 PEEDGTRFHKQASK, PEEDGTRFHMQASK, PEEDGTRFHREASK,  
 PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRQSSK,  
 PEEDGTRFHRQANK, PEEDGTRFHRQASR, PEEDGTRFHRQASL,

- KEEDGTRFHRQASK, PEEDGTRFSRQASK, PEEDGTRFMRQASK, PEEDGTRFHPQASK, PEEDGTRFHSQASK, PEEDGTRFHRTASK, PEEDGTRFHRQTSK, PEEDGTRFHRQASS, PEEDGTRFHRQAST, PEEDGTRFHRQASV, PEEDGSRFHKQASK, PEEDGSRFHMQASK, PEEDGSRFHRRASK, and PEEDGSRFHRQATK; preferably AEEDGTRFHRQASK, PEEDGTRFARQASK, PEEDGTRFHAQASK, PEEDGTRFHRAASK, PEEDGTRFHRQASA, TEEDGTRFHRQASK, PQEDGTRFHRQASK, PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRQSSK, PEEDGTRFSRQASK, PEEDGTRFHPQASK, PEEDGTRFHSQASK, PEEDGTRFHRTASK, PEEDGTRFHRQTSK, PEEDGTRFHRQASS, PEEDGTRFHRQASV, PEEDGSRFHKQASK, PEEDGSRFHRRASK, and PEEDGSRFHRQATK; especially AEEDGTRFHRQASK, PEEDGTRFHAQASK, PQEDGTRFHRQASK, PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRQSSK, PEEDGTRFSRQASK, PEEDGTRFHSQASK, PEEDGTRFHRTASK, PEEDGTRFHRQTSK, PEEDGTRFHRQASS, PEEDGSRFHKQASK and PEEDGSRFHRRASK.
19. 19. Peptide according to any one of embodiments 16 to 18, wherein the peptide consists of 9 to 20 amino acid residues, especially 9 to 15 amino acid residues.
  20. 20. Peptide according to any one of embodiments 16 to 19, wherein the peptide consists of 10, 11, 12, 13, 14 or 15 amino acid residues, preferably 13 or 14 amino acid residues, especially 14 amino acid residues.
  21. 21. Peptide according to any one of embodiments 16 to 20, wherein the peptide has an increased immunogenicity, compared to the peptide PEEDGTRFHRQASK (SEQ.ID.No.1), of at least 50 %, preferably at least 100 %, especially at least 200%, as evidenced in a serum ELISA.
  22. 22. Peptide according to any one of embodiments 16 to 21, wherein the peptide has an increased ability to reduce total cholesterol levels, compared to the peptide PEEDGTRFHRQASK (SEQ.ID.No.1), of at least 3 %, preferably at least 5 %, especially at least 10%, as evidenced in a serum cholesterol test.
  23. 23. Method for treatment of patients having or having a risk of developing disorders caused by hyperlipidemia, hypercholesterolemia and/or atherosclerosis, comprising administering to the patient an effective amount of a vaccine according to any one of embodiments 1 to 15.
  24. 24. Method according to embodiment 23, wherein the disorder is selected from the group consisting of cardiovascular diseases, stroke or peripheral vascular diseases.
  25. 25. Method according to embodiment 23 or 24, wherein preferably subcutaneously, intramuscularly, intradermally, or intravenously.
  26. 26. Method according to any one of embodiments 23 to 25, wherein the vaccine administered contains the at least one peptide in an amount of 0.1 ng to 10 mg, preferably of 0.5 to 500 µg, especially 1 to 100 µg.
  27. 27. Method according to any one of embodiments 23 to 26, wherein the vaccine is applied between 2 and 10, preferably between 2 and 7, and most preferably up to 5 times to the patient.
  28. 28. Method according to any one of embodiments 23 to 27, wherein the vaccine is administered at least twice and wherein the interval of administration is between 2 weeks and 5 years, preferably between 1 month and up to 3 years, more preferably between 2 months and 1.5 years.

29. 29. Method according to any one of embodiments 23 to 28, wherein the vaccine is administered for 3 to 4 initial vaccinations over a period of 6 to 8 weeks and up to 6 months, preferably followed with further administrations after such initial vaccinations.

**SEQUENCE LISTING**

**[0089]**

<110> Affiris AG

<120> Vaccine

<130> R 67027

<150> EP 14157221.4

<151> 2014-02-28

<160> 46

<170> PatentIn version 3.5

<210> 1

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa is an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group consisting of serine, threonine, valine and alanine

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa is an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group of isoleucine, valine, glycine, glutamine and alanine, more preferably isoleucine, valine, glutamine and alanine

<220>

<221> MISC\_FEATURE

<222> (3)..(3)



<210> 2

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> PCSK9 fragment

<400> 2

Ala	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys
1				5						10			

<210> 3

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence

<400> 3

Pro	Ala	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys
1				5						10			

<210> 4

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence

<400> 4

Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	Ala	Arg	Gln	Ala	Ser	Lys
1				5						10			

<210> 5

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 5

Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Ala	Gln	Ala	Ser	Lys
1				5						10			

<210> 6

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 6

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Ala Ala Ser Lys  
1                   5                   10

<210> 7

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 7

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ala Lys  
1                   5                   10

<210> 8

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 8

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Ala  
1                   5                   10

<210> 9

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 9

Thr Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys  
1                   5                   10

<210> 10

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 10

Pro Gln Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys  
1                   5                                   10

<210> 11

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 11

Pro Lys Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys  
1                   5                                   10

<210> 12

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 12

Pro Glu Glu Asp Gly Ser Arg Phe His Arg Gln Ala Ser Lys  
1                   5                                   10

<210> 13

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 13

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys  
1                   5                                   10

<210> 14

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 14

Pro Glu Glu Asp Gly Thr Arg Phe His Lys Gln Ala Ser Lys

1                    5                    10

<210> 15

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 15

Pro Glu Glu Asp Gly Thr Arg Phe His Met Gln Ala Ser Lys  
1                    5                    10

<210> 16

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 16

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Glu Ala Ser Lys  
1                    5                    10

<210> 17

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 17

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Arg Ala Ser Lys  
1                    5                    10

<210> 18

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 18

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Lys Ala Ser Lys  
1                    5                    10

<210> 19

<211> 14



<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 19

Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ser	Ser	Lys
1				5					10				

<210> 20

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 20

Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Thr	Lys
1				5					10				

<210> 21

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 21

Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Asn	Lys
1				5					10				

<210> 22

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 22

Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Leu	Lys
1				5					10				

<210> 23

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 23

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Arg  
1                   5                   10

<210> 24

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 24

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Leu  
1                   5                   10

<210> 25

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 25

Lys Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys  
1                   5                   10

<210> 26

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 26

Pro Glu Trp Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys  
1                   5                   10

<210> 27

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 27

Pro Glu Glu Asp Lys Thr Arg Phe His Arg Gln Ala Ser Lys  
1 5 10

<210> 28

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 28

Pro Glu Glu Asp Gly Thr Gly Phe His Arg Gln Ala Ser Lys  
1 5 10

<210> 29

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 29

Pro Glu Glu Asp Gly Thr Arg Phe Ser Arg Gln Ala Ser Lys  
1 5 10

<210> 30

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 30

Pro Glu Glu Asp Gly Thr Arg Phe Thr Arg Gln Ala Ser Lys  
1 5 10

<210> 31

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 31

Pro Glu Glu Asp Gly Thr Arg Phe Val Arg Gln Ala Ser Lys  
1 5 10

<210> 32

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 32

Pro Glu Glu Asp Gly Thr Arg Phe Gly Arg Gln Ala Ser Lys  
1                   5                   10

<210> 33

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 33

Pro Glu Glu Asp Gly Thr Arg Phe Met Arg Gln Ala Ser Lys  
1                   5                   10

<210> 34

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 34

Pro Glu Glu Asp Gly Thr Arg Phe His Pro Gln Ala Ser Lys  
1                   5                   10

<210> 35

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 35

Pro Glu Glu Asp Gly Thr Arg Phe His Ser Gln Ala Ser Lys  
1                   5                   10

<210> 36

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 36

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Thr Ala Ser Lys  
1                   5                   10

<210> 37

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 37

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Thr Ser Lys  
1                   5                   10

<210> 38

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 38

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Ser  
1                   5                   10

<210> 39

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 39

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Thr  
1                   5                   10

<210> 40

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 40

Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Val  
1                   5                                   10

<210> 41

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 41

Pro Glu Glu Asp Gly Ser Arg Phe His Lys Gln Ala Ser Lys  
1                   5                                   10

<210> 42

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 42

Pro Glu Glu Asp Gly Ser Arg Phe His Met Gln Ala Ser Lys  
1                   5                                   10

<210> 43

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 43

Pro Glu Glu Asp Gly Ser Arg Phe His Arg Arg Ala Ser Lys  
1                   5                                   10

<210> 44

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence, Mimotope

<400> 44

Pro Glu Glu Asp Gly Ser Arg Phe His Arg Gln Ala Thr Lys



- [WO2009055783A2 \[0017\]](#)
- [WO2009100297A1 \[0017\]](#)
- [WO2010057242A2 \[0017\]](#)
- [WO201102757A2 \[0017\]](#)
- [WO2011117401A1 \[0017\]](#)
- [WO201259573A1 \[0017\]](#)
- [WO2013037889A2 \[0017\]](#)
- [WO2013148284A1 \[0017\]](#)
- [EP12182241A \[0032\]](#)
- [WO2013037889A \[0032\]](#)
- [WO9118926A \[0042\]](#)
- [GB2122204B \[0046\]](#)
- [GB2220211A \[0046\]](#)
- [US4912094A \[0046\] \[0046\]](#)
- [WO9421292A \[0046\]](#)
- [WO9843670A \[0046\]](#)
- [US4436727A \[0046\]](#)
- [US4877611A \[0046\]](#)
- [US4866034A \[0046\]](#)
- [WO9602555A \[0047\] \[0047\] \[0047\]](#)
- [WO9933488A \[0047\]](#)
- [US6008200A \[0047\]](#)
- [US5856462A \[0047\]](#)
- [WO9816247A \[0047\]](#)
- [EP0468520A \[0047\]](#)
- [WO9400153A \[0048\]](#)
- [WO9633739A \[0048\] \[0048\]](#)
- [WO9517210A \[0048\]](#)
- [WO9611711A \[0048\]](#)
- [US5057540A \[0048\]](#)
- [EP0362279B1 \[0048\]](#)
- [WO2005112991A \[0049\]](#)
- [EP14157221A \[0089\]](#)

#### Non-patent literature cited in the description

- **LUO et al.**J. Lipid Res., 2009, vol. 50, 1581-1588 [\[0017\]](#)



- **SINGH et al.** Nat. Biotech., 1999, vol. 17, 1075-1081 [\[0041\]](#)
- **O'HAGANVALIANTE** Nature Reviews Drug Discovery, 2003, vol. 2, 9727-735 [\[0041\]](#)
- **GREG T. HERMANSON** Bioconjugate Techniques [\[0041\]](#)
- Gene, 1986, vol. 43, 265-292 [\[0042\]](#)
- **RIBI et al.** Immunology and Immunopharmacology of Bacterial Endotoxins Plenum Publ. Corp. 19860000407-419 [\[0046\]](#)
- **SATO et al.** Science, 1996, vol. 273, 352- [\[0047\]](#)
- **BRAZOLOT-MILLAN et al.** PNAS USA, 1998, vol. 95, 2615553-8 [\[0047\]](#)
- **DAVIS et al.** J. Immunol, 1998, vol. 160, 2870-876 [\[0047\]](#)
- **MCCLUSKIEDAVIS** J. Immunol., 1998, vol. 161, 94463-6 [\[0047\]](#)
- **O'HAGAN et al.** Nature Reviews Drug Discovery, 2003, vol. 2, 9727-735 [\[0051\]](#)
- **SUN et al.** Neoplasia, 2012, vol. 14, 121122-1131 [\[0052\]](#)
- **STEINBERG, D.J** Lipid Res, 2005, vol. 46, 179-190 [\[0056\]](#)
- **STEINBERG, D.J** Lipid Res, 2006, vol. 47, 1339-1351 [\[0056\]](#)

**Patentkrav**

**1.** Vaccine omfattende mindst ét peptid, valgt fra gruppen bestående af PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRTASK, PEEDGSRFHKQASK, og PEEDGSRFHRQATK.

5

**2.** Vaccine omfattende mindst ét peptid, valgt fra gruppen bestående af PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRTASK, PEEDGSRFHKQASK, og PEEDGSRFHRQATK til anvendelse i reduktion af plasma-LDL-cholesterol-niveauer.

10

**3.** Vaccine ifølge krav 1 eller til anvendelse ifølge krav 2, hvor det mindst ene peptid er koblet eller fusioneret til en farmaceutisk acceptabel bærer.

**4.** Vaccine ifølge krav 1 eller 3 eller til anvendelse ifølge krav 2 eller 3, hvor det mindst ene peptid omfatter ved dets N- og/eller C-terminus mindst én cysteinrest bundet direkte eller via en spacersekvens dertil.

**5.** Vaccine ifølge krav 3 eller 4 eller til anvendelse ifølge krav 3 eller 4, hvor den farmaceutisk acceptable bærer er en proteinbærer.

20

**6.** Vaccine ifølge krav 5 eller til anvendelse ifølge krav 5, hvor proteinbæreren er valgt fra gruppen bestående af keyhole limpet haemocyanin (KLH), tetanustoxoid (TT), CRM197, protein D eller et difteritoxin (DT), fortrinsvis et muteret difteritoxin, CRM197, eller KLH, især KLH.

25

**7.** Vaccine ifølge et hvilket som helst af kravene 1 og 3 til 6 eller til anvendelse ifølge kravene 2 til 6, hvor vaccinen er formuleret med en adjuvans, fortrinsvis med Al(OH)<sub>3</sub> (Alhydrogel).

**8.** Vaccine ifølge et hvilket som helst af kravene 1 og 3-7 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af hyperlipidæmi, hypercholesterolæmi, atherosclerose, fortrinsvis cardiovaskulære sygdomme, slagtilfælde eller perifere vaskulære sygdomme, perifer arteriel, okklusiv sygdom,

coronar hjertesygdom, apoplektisk cerebral insultus; eller neoplastiske sygdomme, fortrinsvis melanom og levercancermetastaser forbundet med PCSK9.

**9.** Peptid bestående af en aminosyresekvens valgt fra gruppen bestående af  
5 PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRTASK, PEEDGSRFHKQASK,  
og PEEDGSRFHRQATK.

**10.** Peptid bestående af en aminosyresekvens valgt fra gruppen bestående af  
10 PEEDGTRFHRRASK, PEEDGTRFHRKASK, PEEDGTRFHRTASK, PEEDGSRFHKQASK,  
og PEEDGSRFHRQATK til anvendelse i reduktion af plasma  
LDL-cholesterolniveauer.

**11.** Peptid ifølge krav 9 til anvendelse til behandling af patienter der har eller har  
15 risiko for at udvikle hyperlipidæmi, hypercholesterolæmi og/eller atherosclerose,  
fortrinsvis cardiovaskulære sygdomme, slagtilfælde eller perifere vaskulære  
sygdomme, perifer arteriel, okklusiv sygdom, coronar hjertesygdom, apoplektisk  
cerebral insultus; eller neoplastiske sygdomme, fortrinsvis melanom og  
levercancermetastaser forbundet med PCSK9.

# DRAWINGS

Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 2C




Figure 3




Figure 4




Figure 5






Figure 6

